{
    "ticker": "BLPH",
    "name": "Bellerophon Therapeutics, Inc.",
    "description": "Bellerophon Therapeutics, Inc. is a clinical-stage biotherapeutics company focused on developing innovative therapies for patients with severe and life-threatening conditions. Founded in 2015, Bellerophon is dedicated to addressing unmet medical needs through its proprietary technology platform that harnesses the potential of nitric oxide. The company is primarily known for its lead product candidate, INOpulse, which is designed for the treatment of pulmonary hypertension and other serious pulmonary conditions. INOpulse delivers inhaled nitric oxide directly to the lungs, providing a targeted and efficient therapeutic approach. Bellerophon is committed to advancing its pipeline of therapies, which includes candidates for various indications, including pulmonary diseases and COVID-19. By leveraging its expertise in nitric oxide and drug delivery technologies, Bellerophon aims to improve patient outcomes and quality of life. The company is headquartered in Warren, New Jersey, and is actively engaged in clinical trials to validate the safety and efficacy of its treatments. With a focus on innovation, Bellerophon seeks to make a meaningful impact in the field of pulmonary medicine and beyond.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Warren, New Jersey, USA",
    "founded": "2015",
    "website": "https://www.bellerophon.com",
    "ceo": "Ross D. Barrett",
    "social_media": {
        "twitter": "https://twitter.com/BellerophonTx",
        "linkedin": "https://www.linkedin.com/company/bellerophon-therapeutics/"
    },
    "investor_relations": "https://www.bellerophon.com/investors",
    "key_executives": [
        {
            "name": "Ross D. Barrett",
            "position": "CEO"
        },
        {
            "name": "David E. Dodd",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "INOpulse"
            ]
        }
    ],
    "seo": {
        "meta_title": "Bellerophon Therapeutics, Inc. | Innovative Pulmonary Therapies",
        "meta_description": "Bellerophon Therapeutics, Inc. is a clinical-stage company developing innovative therapies for pulmonary conditions, including INOpulse for pulmonary hypertension.",
        "keywords": [
            "Bellerophon",
            "Pulmonary Hypertension",
            "INOpulse",
            "Nitric Oxide",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Bellerophon Therapeutics known for?",
            "answer": "Bellerophon Therapeutics is known for developing innovative therapies for pulmonary conditions, particularly its lead product candidate INOpulse."
        },
        {
            "question": "Who is the CEO of Bellerophon Therapeutics?",
            "answer": "Ross D. Barrett is the CEO of Bellerophon Therapeutics, Inc."
        },
        {
            "question": "Where is Bellerophon headquartered?",
            "answer": "Bellerophon is headquartered in Warren, New Jersey, USA."
        },
        {
            "question": "What is INOpulse?",
            "answer": "INOpulse is Bellerophon's lead product candidate for the treatment of pulmonary hypertension, delivering inhaled nitric oxide directly to the lungs."
        },
        {
            "question": "When was Bellerophon Therapeutics founded?",
            "answer": "Bellerophon Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "NVS",
        "VRTX",
        "AMGN",
        "BMY"
    ],
    "related_stocks": [
        "GILD",
        "JNJ",
        "PFE",
        "MRK"
    ]
}